Home › Squamous Cell Carcinoma ng Ulo at Leeg › Oklahoma › Oklahoma City
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Oklahoma City, OK
Isang pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Oklahoma City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Nagre-recruitPhase 3
- Stephenson Cancer Center, Oklahoma City
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Oklahoma City
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Nagre-recruitPhase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- SSM OKC Hightower Clinical, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Nagre-recruitPhase 1
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of Oklahoma, Oklahoma City
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- Nashville, TN39 pag-aaral
- New York City, NY39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Chicago, IL26 pag-aaral
- Philadelphia, PA25 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- Pittsburgh, PA22 pag-aaral
Iba pang pag-aaral sa Oklahoma City
- Kanser sa Ovary28 pag-aaral
- Non-Small Cell Lung Cancer28 pag-aaral
- Kanser ng Endometrium25 pag-aaral
- Colorectal Cancer22 pag-aaral
- Kanser sa Prostate21 pag-aaral
- Kanser sa Baga19 pag-aaral
- Kanser sa Suso17 pag-aaral
- Metastatic Cancer16 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Kanser sa Pancreas11 pag-aaral
- Kanser sa Pantog11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 7, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.